about
Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenPhosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsyCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Characteristics of thoracolumbar intramedullary subependymomas.Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation.A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.Lactoferrin Is an Allosteric Enhancer of the Proteolytic Activity of Cathepsin G.Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.Lumbar subdural haematoma after temporomesial resection in epilepsy patients--report of two cases and review of the literature.Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivoTherapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?Exogenous cathepsin G upregulates cell surface MHC class I molecules on immune and glioblastoma cells.Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.The rationale of targeting neutrophils with dapsone during glioblastoma treatment.Erlotinib in glioblastoma: lost in translation?Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma.Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.Cell Death Induction in Cancer Therapy - Past, Present, and Future.Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.RIST: a potent new combination therapy for glioblastoma.Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells.A paired comparison between glioblastoma "stem cells" and differentiated cells.Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
P50
Q26749972-F61457DA-D203-49D6-9166-A32755FA8C1DQ33687799-7178CE78-DE1C-45FD-B2E3-2B94DEABE4CEQ34437996-9449DBE2-F51D-4067-A0D1-4E038130643BQ34914113-F1A21390-30DB-4B8B-A823-F88023AA08E5Q34966234-6252BA88-BEB0-4701-9B67-DAECBFAB6F8AQ35677134-9F86B3D9-9843-4619-AF84-FD380FF03C89Q35961015-D454E691-4706-4886-8B74-9081B84E29A5Q35987399-74AB2F6A-4B14-4614-8DFA-CB7814ECA23CQ36400537-BDF2326F-F194-4F47-BD0E-446A15B9A36DQ36546689-9A03A3B9-DE4B-4ABA-90F5-D484CB0F07BFQ36756236-4A3CC542-1771-4356-B4EC-C58113FF1F2AQ37022290-5F9C50F2-FCE0-4B80-9650-F7EB4DA46C53Q37376084-4D6BDC42-92AC-411A-B51D-CFE822CEE8D9Q37543816-6EC23D21-46B7-4379-9F99-D4A62F0BEC5CQ37688825-BE90F4D7-6EC8-4DF3-A911-72A9DB55E14FQ37879709-73756A4B-7092-4D37-8F4B-F8D037F80623Q37894778-35F7348C-6B27-4990-AE55-E36089E34C44Q37894779-F9B4AC4B-C8D5-4A3F-8A92-93D8EC6FE966Q38008063-44910F55-3AD3-4F79-AE4A-737B7FEC7C06Q38161391-A5B10BE4-A713-4546-B060-51DCD1B8712BQ38602644-BEA9A50B-2965-46EC-8AF6-E645CE0AF3C6Q38677019-D76039C5-198E-4FC6-9959-60D3F47B84FAQ38787462-CB135E26-B0E5-4C57-B483-7802B1C22DC3Q38811369-25A16283-88E6-43B9-AF16-D08F14D167DBQ38926314-F061CC85-FE67-4453-9ACA-8D86F6F3C1BCQ38927030-A9DFA66A-044B-429B-AB30-E135FCF89C1EQ38966022-828D9F26-5AB0-4EE6-917F-13FEDD361CA7Q39026144-C65213F1-6FA9-4ABC-953F-FD85D8965503Q39075237-79A636E3-CB01-450B-8E63-380A247F71B8Q39129269-33D00421-9A9F-45F0-A713-324AD62F5507Q39202839-C27A31BB-59E9-4E32-9D06-88BC8BA134DDQ40373080-5B8B9B30-5FEB-4F0C-A479-D22E2994EA44Q40567286-B1CEB750-B876-4EDB-A8AE-1997AD57EA24Q40575526-D7DE632D-270B-4581-9E83-D48AF869C82D
P50
description
onderzoeker
@nl
name
Marc-Eric Halatsch
@ast
Marc-Eric Halatsch
@en
Marc-Eric Halatsch
@es
Marc-Eric Halatsch
@sl
type
label
Marc-Eric Halatsch
@ast
Marc-Eric Halatsch
@en
Marc-Eric Halatsch
@es
Marc-Eric Halatsch
@sl
prefLabel
Marc-Eric Halatsch
@ast
Marc-Eric Halatsch
@en
Marc-Eric Halatsch
@es
Marc-Eric Halatsch
@sl